Abstract
This pooled analysis evaluated the relationship of isavuconazole and voriconazole MICs of Aspergillus pathogens at baseline with all-cause mortality and clinical outcomes following treatment with either drug in the SECURE and VITAL trials. Isavuconazole and voriconazole may have had reduced efficacy against pathogens with drug MICs of ≥16 µg/ml, but there was no relationship with clinical outcomes in cases where the MIC was <16 µg/ml for either drug.
Keywords:
MIC; clinical trial; isavuconazole; isavuconazonium sulfate; voriconazole.
Copyright © 2018 Andes et al.
Publication types
-
Clinical Trial, Phase III
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Antifungal Agents / therapeutic use*
-
Aspergillosis / drug therapy*
-
Aspergillosis / microbiology
-
Aspergillosis / mortality
-
Aspergillus / drug effects*
-
Aspergillus / isolation & purification
-
Humans
-
Invasive Fungal Infections / drug therapy
-
Invasive Fungal Infections / microbiology
-
Microbial Sensitivity Tests
-
Nitriles / therapeutic use*
-
Pyridines / therapeutic use*
-
Triazoles / therapeutic use*
-
Voriconazole / therapeutic use*
Substances
-
Antifungal Agents
-
Nitriles
-
Pyridines
-
Triazoles
-
isavuconazole
-
Voriconazole